Vertex Pharmaceuticals Incorporated
VRTXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeVertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. At a $134.06B market cap, Vertex Pharmaceuticals Incorporated ranks as a large-cap company within healthcare. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
Market Cap
$134.06B
Beta
0.32
P/E (TTM)
30.84
P/E (Fwd)
26.15
EPS (TTM)
$17.15
EPS (Fwd)
$20.23
ROE
23.5%
ROA
11.9%
Cash
$7.85B
Total Debt
$1.98B
Free CF
$2.63B
52W Change
40.6%
Annual Financials
Cash vs Debt
Where VRTX stands vs its 150-day and 200-day moving averages
As of the August 27, 2026 close, VRTX finished 17.12% above its 150-day moving average ($467.30) and 18.48% above its 200-day moving average ($461.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VRTX overbought or oversold?
At the August 27, 2026 close, VRTX's RSI(14) was 71.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Vertex Pharmaceuticals Incorporated holds $7.85B in cash against $1.98B in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow comes in at $2.63B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 23.5% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 11.9% further supports the picture of efficient asset utilization. Revenue has grown from $8.93B (2022) to $12.00B (2025), reflecting a 34% increase over the period.
The relatively low beta of 0.32 suggests VRTX is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, VRTX has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Vertex Pharmaceuticals Incorporated and its sector.